Prognostic factors in stage I/II non-small cell lung cancer.
Even in localized stages of non-small cell lung cancer, which are amenable to curative surgery, prognosis has remained disappointing over the last decades. Thus, in these tumor stages, adjuvant therapy strategies are discussed. In the last decade, numerous prognostic factors have been investigated, which might select patients for additional treatment. In this review, the prognostic impact of individual tumor cell dissemination, tumor cell proliferation, apoptosis, several parameters of angiogenesis (microvessel density, VEGF, bFGF, VEGF receptors), p53, bcl-2, ras, p27(Kip1), erbB-2, telomerase as well as the retinoblastoma tumor suppressor gene is analysed. Up to now, none of these factors has gained a sufficient selectivity to serve as an exclusive discriminator for adjuvant therapy. Nevertheless, a combination of several parameters might contribute to characterize patient subgroups with localized non-small cell lung cancer at high risk for distant relapse.
Junker
K
K
Institute of Pathology, Bergmannsheil-University Hospital, Bochum, Bürkle-de-la-Camp-Platz 1, D-44789, Bochum, Germany. klaus.junker@ruhr-uni-bochum.de
D014408:Biomarkers, Tumor / Q000032:analysis; D002289:Carcinoma, Non-Small-Cell Lung / Q000737:chemistry / Q000145:classification / Q000175:diagnosis*; D006801:Humans; D008175:Lung Neoplasms / Q000737:chemistry / Q000145:classification / Q000175:diagnosis*; D009367:Neoplasm Staging; D011379:Prognosis
D014408:Biomarkers, Tumor